Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

$1.32
0.07 (5.18%)
NASDAQ Global Market
USD, US
Biotechnology

FATE Price Chart

Basic
Market Cap$179.84M
Price$1.32
52 Week Range1.57-8.83
Beta1.88
Margins
Gross Profit Margin-229.52%
Operating Profit Margin-1462.06%
Net Profit Margin-1325.43%
Valuation (TTM)
P/E Ratio-0.87
Price to Sales Ratio11.18
Price to Book Ratio0.43
PEG Ratio-0.25

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

181

IPO Date

2013-10-01T00:00:00.000Z

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Phone

858 875 1800

Address

12278 Scripps Summit Drive, San Diego, CA, 92131, US

CIK

0001434316